Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway

References

• Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 2011;129:709–717
   PubMedGoogle Scholar
• Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502–508
   PubMed Web of Science ®Google Scholar
• Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmol 2013;120:106–114
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmol 2012;119:2537–2548
   PubMed Web of Science ®Google Scholar
• Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmol 2013;120:130–139
   PubMed Web of Science ®Google Scholar
• Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmol 2011;118:663–671
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmol 2011;118:831–839
   PubMed Web of Science ®Google Scholar
• Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606–1611
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431
   PubMed Web of Science ®Google Scholar
• Campbell RJ, Bell CM, Paterson JM, et al. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Ophthalmol 2012;119:1604–1608
   PubMed Web of Science ®Google Scholar
• French DD, Margo CE. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina 2011;31:1036–1042
   PubMedGoogle Scholar
• Nuzzi R, Tridico F. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. Seminars in Ophthalmology 2013. [Epub ahead of print]
   Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27:787–794
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95–113
   PubMed Web of Science ®Google Scholar
• Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009;148:647–656
   PubMed Web of Science ®Google Scholar
• Dombi T, Kwok KK, Sultan MB. A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus. BMC Ophthalmology 2012;12:37
   PubMedGoogle Scholar
• Higashide T, Murotani E, Saito Y, et al. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2012;250:603–610
   PubMedGoogle Scholar
• Rasier R, Artunay O, Yuzbasioglu E, et al. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond) 2009;23:1714–1718
   PubMed Web of Science ®Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465–477
   PubMed Web of Science ®Google Scholar
• Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opini Drug Saf 2006;5:553–566
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985
   PubMed Web of Science ®Google Scholar
• Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549–580
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006;9:225–230; discussion 231
   PubMedGoogle Scholar
• Nowak DG, Amin EM, Rennel ES, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Bio Chem 2010;285:5532–5540
   PubMed Web of Science ®Google Scholar
• Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF: a to treat cancer and age-related macular degeneration. Annu Rev Med 2007;58:491–504
   PubMed Web of Science ®Google Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227–241
   PubMed Web of Science ®Google Scholar
• Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992;114:521–532
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435–439
   PubMed Web of Science ®Google Scholar
• Peters KG, De Vries C, Williams LT. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA 1993;90:8915–8919
   PubMed Web of Science ®Google Scholar
• Choi K, Kennedy M, Kazarov A, et al. A common precursor for hematopoietic and endothelial cells. Development 1998;125:725–732
   PubMed Web of Science ®Google Scholar
• Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423–1425
   PubMed Web of Science ®Google Scholar
• Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946–949
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–66
   PubMed Web of Science ®Google Scholar
• Cudmore MJ, Hewett PW, Ahmad S, et al. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nature Communications 2012;3:972
   PubMed Web of Science ®Google Scholar
• Bao P, Kodra A, Tomic-Canic M, et al. The role of vascular endothelial growth factor in wound healing. J Surg Res 2009;153:347–358
   PubMed Web of Science ®Google Scholar
• Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Meta 1996;81:353–359
   PubMed Web of Science ®Google Scholar
• Brouillet S, Hoffmann P, Feige JJ, Alfaidy N. EG-VEGF: a key endocrine factor in placental development. Trends Endocrinol Metab 2012;23:501–508
   PubMed Web of Science ®Google Scholar
• Luo J, Xiong Y, Han X, Lu Y. VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications. J Mol Med (Berl) 2011;89:635–645
   PubMed Web of Science ®Google Scholar
• Jin K, Zhu Y, Sun Y, et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 2002;99:11946–11950
   PubMed Web of Science ®Google Scholar
• Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000;97:10242–10247
   PubMed Web of Science ®Google Scholar
• Gora-Kupilas K, Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia neuropathologica/Assoc of Polish Neuropathol and Med Res Cen, Polish Acad of Sci 2005;43:31–39
   PubMedGoogle Scholar
• Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 2008;3:e3554
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor: a is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53–67
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118:523–530
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10–14
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age–related macular degeneration. N Engl J Med 2004;351:2805–2816
   PubMed Web of Science ®Google Scholar
• Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408–2413
   PubMed Web of Science ®Google Scholar
• Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Exp rev of clin pharmacol 2014;7:167–180
   PubMed Web of Science ®Google Scholar
• Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharmaceutical Research 2000;17:1503–1510
   PubMed Web of Science ®Google Scholar
• Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmol 2007;114:1702–1712
   PubMed Web of Science ®Google Scholar
• Macugen (pegaptanib) [package insert]. U.S. Full Prescribing Information; Cedar Knolls, NJ: Eyetech Inc., 2008
   Google Scholar
• Lucentis (ranibizumab) [package insert]. U.S. Full Prescribing Information; South San Francisco, CA: Genentech, Inc., 2014
   Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536–544
   PubMed Web of Science ®Google Scholar
• Xu L JN, Eppler S, Lu J, Damico L, Joshi A. Population pharmacokinetics of ranibizumab in patients with age-related macular degeneration. American Association of Pharmaceutical Scientists meeting. San Antonio, TX 29 October--2 November 2006
   Google Scholar
• Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154:682–686
   PubMed Web of Science ®Google Scholar
• Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002;9:152–166
   PubMedGoogle Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859–870
   PubMed Web of Science ®Google Scholar
• Eylea (afilbercept) [package insert]. U.S. Full Prescribing Information; Tarrytown, NY: Regeneron, Inc., 2014
   Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171–185
   PubMed Web of Science ®Google Scholar
• Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222–226
   PubMed Web of Science ®Google Scholar
• Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol 2012;96:1157–1158
   PubMed Web of Science ®Google Scholar
• Avastin(bevacizumab) [package insert]. U.S. Full Prescribing Information; South San Francisco, CA: Genentech, Inc., 2013
   Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331–335
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmol 2012;119:1399–1411
   PubMedGoogle Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmol 2012;119:1388–1398
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908
   PubMed Web of Science ®Google Scholar
• Schmucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011;95:308–317
   PubMed Web of Science ®Google Scholar
• Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31:1877–1884
   PubMed Web of Science ®Google Scholar
• Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915–930
   PubMed Web of Science ®Google Scholar
• Simha A, Braganza A, Abraham L, et al. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Sys Rev 2013;10:CD007920
   Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603–615
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews: Cancer 2008;8:579–591
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Reviews: Drug Discovery 2006;5:123–132
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158–165
   PubMed Web of Science ®Google Scholar
• Ahn SJ, Ahn J, Park S, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2014;55:567–573
   PubMed Web of Science ®Google Scholar
• Christoforidis JB, Xie Z, Jiang A, et al. Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non–surgical controls. Current Eye Research 2013;38:761–766
   PubMed Web of Science ®Google Scholar
• Kakinoki M, Sawada O, Sawada T, et al. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci 2012;53:5877–5880
   PubMed Web of Science ®Google Scholar
• Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006;26:871–876
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nature Medicine 2013;19:1584–1596
   PubMed Web of Science ®Google Scholar
• Chuang LH, Wu WC, Yeung L, et al. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion. Ophthalmic Research 2011;45:31–35
   PubMed Web of Science ®Google Scholar
• Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982;26:207–218
   PubMed Web of Science ®Google Scholar
• Davidovic SP, Nikolic SV, Curic NJ, et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J Ophthalmol 2012;22:792–798
   PubMed Web of Science ®Google Scholar
• Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011;31:161–168
   PubMed Web of Science ®Google Scholar
• Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215–1218
   PubMed Web of Science ®Google Scholar
• Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmologica 2012;90:e25–e30
   PubMed Web of Science ®Google Scholar
• Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 2013;98(Suppl 1):i7--i10
   Google Scholar
• Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmol 2006;113:e1--15
   PubMed Web of Science ®Google Scholar
• Scartozzi R, Chao JR, Walsh AC, Eliott D. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:1229
   PubMedGoogle Scholar
• Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327–333
   PubMed Web of Science ®Google Scholar
• Meyer CH, Krohne TU, Holz FG. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmologica 2012;90:68–70
   PubMed Web of Science ®Google Scholar
• Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010;51:1606–1608
   PubMed Web of Science ®Google Scholar
• Wang D, Choi KS, Lee SJ. Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Korean J Ophthalmol 2014;28:32–38
   PubMedGoogle Scholar
• Velez-Montoya R, Fromow-Guerra J, Burgos O, et al. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 2009;29:20–26
   PubMed Web of Science ®Google Scholar
• Forooghian F, Chew EY, Meyerle CB, et al. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmologica 2011;89:e206–e207
   Google Scholar
• Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 2011;408:276–281
   PubMed Web of Science ®Google Scholar
• Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 2012;7:e42701
   PubMed Web of Science ®Google Scholar
• Vedula SS, Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008;2:CD005139
   Google Scholar
• Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2014;5:CD007325
   PubMed Web of Science ®Google Scholar
• Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013;1:CD009510
   Google Scholar
• Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2012;12:CD007419
   PubMedGoogle Scholar
• Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targ Oncol 2009;4:67–76
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232–1239
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–65
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672–4678
   PubMed Web of Science ®Google Scholar
• Enseleit F, Michels S, Ruschitzka F. Anti-VEGF therapies and blood pressure: more than meets the eye. Curr Hypertens Rep 2010;12:33–38
   PubMedGoogle Scholar
• Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356:747–748; author reply 749–750
   PubMed Web of Science ®Google Scholar
• Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab. Retina 2013;33:508–512
   PubMed Web of Science ®Google Scholar
• Davis A, Cohen SM, Pautler SE, et al. Beta blocker use and age-related macular degeneration. Acta Ophthalmologica 2012;90:e162–e163
   PubMedGoogle Scholar
• Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmol 2013;120:2004–2012
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmol 2006; 113:1522
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmol 2014;121:193–201
   PubMed Web of Science ®Google Scholar
• Salman AG. Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension. Saudi J Ophthalmol 2013;27:25–29
   PubMedGoogle Scholar
• Zucchiatti I, Iacono P, Battaglia PM, et al. Intravitreal bevacizumab in a patient with a macular star in malignant hypertension. Eur J Ophthalmol 2011;21:336–339
   PubMedGoogle Scholar
• Barron H. Genentech: important drug warning (letter); South San Francisco, CA: US Food and Drug Administration: MedWatch, 2005
   Google Scholar
• Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmol 2009;116:1731–1739
   PubMed Web of Science ®Google Scholar
• Barron H. Genentech: important drug warning (letter); South San Francisco, CA: US Food and Drug Administration: MedWatch, 2007
   Google Scholar
• Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32:1821–1828
   PubMed Web of Science ®Google Scholar
• Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmol 2009;116:362
   PubMed Web of Science ®Google Scholar
• Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273–1279
   PubMed Web of Science ®Google Scholar
• Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203
   PubMed Web of Science ®Google Scholar
• Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46:439–448
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–2676
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–2550
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–2111
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129–1136
   PubMed Web of Science ®Google Scholar
• Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007;22:1481–1482
   PubMedGoogle Scholar
• Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745–1747
   PubMed Web of Science ®Google Scholar
• Georgalas I, Papaconstantinou D, Papadopoulos K, et al. Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease: a possible side effect? Current Drug Safety 2014. [Epub ahead of print]
   Google Scholar
• Jamrozy-Witkowska A, Kowalska K, Jankowska-Lech I, et al. Complications of intravitreal injections–own experience. Klinika Oczna 2011;113:127–131
   PubMedGoogle Scholar
• Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmol 2007;114:1860–1867
   PubMedGoogle Scholar
• Pelle G, Shweke N, Duong Van Huyen JP, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis 2011;57:756–759
   PubMed Web of Science ®Google Scholar
• Steffensmeier AC, Azar AE, Fuller JJ, et al. Vitreous injections of pegaptanib sodium triggering allergic reactions. Am J Ophthalmol 2007;143:512–513
   PubMedGoogle Scholar
• Toklu Y, Sarac O, Berk S, Simsek S. Angioedema after intravitreal bevacizumab injection. Cutan Ocul Toxicol 2012;31:85–86
   PubMed Web of Science ®Google Scholar
• Petrou P, Georgalas I, Giavaras G, et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmologica 2010;88:e136
   PubMed Web of Science ®Google Scholar
• Tarantola RM, Folk JC, Boldt HC, Mahajan VB. Intravitreal bevacizumab during pregnancy. Retina 2010;30:1405–1411
   PubMed Web of Science ®Google Scholar
• Introini U, Casalino G, Cardani A, et al. Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. J Ocul Pharmacol Ther 2012;28:553–555
   PubMed Web of Science ®Google Scholar
• Sullivan L, Kelly SP, Glenn A, et al. Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond) 2014;28:492–494
   PubMed Web of Science ®Google Scholar
• Cross SN, Ratner E, Rutherford TJ, et al. Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol 2012;5:2–8
   PubMedGoogle Scholar
• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochemis 2013;153:13–19
   PubMed Web of Science ®Google Scholar
• Yohendran J, Chauhan D. Erectile dysfunction following intravitreal bevacizumab. Middle East Afr J Ophthalmol 2010;17:281–284
   PubMedGoogle Scholar
• Meyer CH, Mennel S, Horle S, Schmidt JC. Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 2007;143:169–170
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487–494
   PubMed Web of Science ®Google Scholar